MedTrace Logo

Kidney Damage in Patients With Moderate Fall in eGFR

NCT01136876 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-11-04

Study results available
· View outcomes & findings →

Summary

To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR

Conditions

  • Coronary Artery Stenosis

Interventions

DRUG

Iopamidol

Iopamidol 370, one time administration for percutaneous coronary intervention

DRUG

Iodixanol-320

Iodixanol-320 single administration for percutaneous coronary intervention procedure

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Maria Luigia Storto, MD · Bracco Diagnostics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136876 on ClinicalTrials.gov